title: Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
authors.forename: Yatan Pal Singh
authors.initials: YP
authors.lastname: Balhara
mesh_terms: D000701:Analgesics, Opioid / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D002047:Buprenorphine / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D000069479:Buprenorphine, Naloxone Drug Combination; D018954:Drugs, Essential / Q000145:classification / Q000627:therapeutic use*; D006801:Humans; D009270:Naloxone / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D058850:Opiate Substitution Treatment; D009293:Opioid-Related Disorders / Q000188:drug therapy*; D064226:Prescription Drug Diversion / Q000517:prevention & control; D014944:World Health Organization
chemical_list: D000701:Analgesics, Opioid; D000069479:Buprenorphine, Naloxone Drug Combination; D018954:Drugs, Essential; D009292:Narcotic Antagonists; D009270:Naloxone; D002047:Buprenorphine